Neurology Focused Clinical Research

Comprehensive neurology clinical trial support across neurodegenerative diseases, epilepsy, multiple sclerosis, and neuromuscular disorders — with expertise in complex cognitive endpoints and longitudinal assessment.

Overview

Expertise in Complex Neurological Research

Neurological clinical trials present unique challenges: long follow-up periods, subjective clinical endpoints, slow progression rates, and the need for highly specialized site networks with experienced raters. Omega CRO brings deep expertise in designing and executing neurology trials that address these complexities head-on.

Our experience spans the full range of central nervous system (CNS) and peripheral nervous system disorders. We understand the critical importance of standardized cognitive assessments, biomarker-guided patient stratification, CSF sample management, and the integration of digital health technologies for remote monitoring of neurological function.

Therapeutic Coverage

Neurological Indications

Neurodegenerative Diseases

  • Alzheimer's Disease & Mild Cognitive Impairment
  • Parkinson's Disease
  • Amyotrophic Lateral Sclerosis (ALS)
  • Huntington's Disease

Demyelinating & Inflammatory

  • Multiple Sclerosis (RRMS, SPMS, PPMS)
  • Neuromyelitis Optica Spectrum Disorder (NMOSD)
  • Myasthenia Gravis
  • Autoimmune Encephalitis

Epilepsy & Neuromuscular

  • Focal & Generalized Epilepsy
  • Spinal Muscular Atrophy (SMA)
  • Duchenne Muscular Dystrophy (DMD)
  • Migraine & Cluster Headache
Specialized Assessments

Cognitive, Motor & Biomarker Endpoints

Neurology trials require validated, standardized assessment tools administered by trained raters across multiple sites.

Cognitive & Functional Assessments

  • MMSE, ADAS-Cog, CDR-SB for Alzheimer's trials
  • MDS-UPDRS for Parkinson's Disease
  • EDSS for Multiple Sclerosis
  • ALSFRS-R for ALS progression
  • Central rater training and certification programs

Biomarkers & Laboratory Support

  • CSF biomarker analysis (Aβ42, p-tau, t-tau, NfL)
  • Plasma NfL and GFAP for neurodegeneration monitoring
  • Anti-AQP4 and anti-MOG antibody testing for NMOSD
  • CSF sample collection, processing, and biobanking
  • Genetic testing for hereditary neurological disorders
Innovation

Digital Health & Decentralized Solutions

Leveraging wearable sensors, smartphone-based cognitive assessments, and remote monitoring to capture richer neurological data.

Wearable Motor Assessment

Smartwatch and body-worn sensors for continuous tremor, gait, and bradykinesia monitoring in Parkinson's trials.

Remote Cognitive Testing

Tablet-based and telehealth cognitive assessments enabling decentralized trial visits and reducing site burden.

ePRO & Home Monitoring

Electronic patient-reported outcomes and home-based assessments for seizure diaries, pain scales, and quality of life.

Omega Research Ecosystem

Application Scenarios in the Omega Ecosystem

How the Omega ecosystem supports neurology research\u2014from CSF biomarker analysis to genetic confirmation and remote cognitive monitoring.

HelixLab

Neuro-Specific Safety Panels

CSF cell count and protein analysis, plasma neurofilament light chain (NfL), GFAP, routine safety labs, and anti-epileptic drug (AED) level monitoring with strict pre-analytical CSF protocols.

Omega Genetics

Neurodegenerative Gene Panels

CSF A\u03b242, p-tau181, t-tau for Alzheimer\u2019s; LRRK2, GBA, SNCA for Parkinson\u2019s; C9orf72, SOD1, TARDBP for ALS; SMN1/SMN2 copy number for SMA diagnosis and trial eligibility.

Omega Biorepository

CSF & Plasma Biobanking

Paired CSF-plasma aliquots processed within 60 minutes of collection, stored at -80\u00b0C with ISBER-aligned protocols for retrospective biomarker discovery and validation.

Omega Care

Remote Cognitive Testing

Tablet-based MMSE and ADAS-Cog administration at home; wearable motor assessment (tremor, gait) for Parkinson\u2019s; seizure diary and PRO capture via TURP digital health platform.

Omega Bio

AChR & MOG Antibody Kits

Kit-based standardization for anti-AChR, anti-MOG, and anti-NMDAR antibody assays; CSF/serum paired testing harmonization across sites for autoimmune neurology trials.

Animal Facility

Neurological Disease Models

APP/PS1 transgenic Alzheimer\u2019s models, MPTP and 6-OHDA Parkinson\u2019s models, SOD1-G93A ALS models, and EAE multiple sclerosis models for preclinical neurology drug evaluation.

Advance Your Neurology Research Program

Partner with Omega CRO for specialized neurological clinical trial expertise and integrated laboratory support.

Talk to Our Experts